Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents
Aims. To compare visual and anatomic outcomes of adjunct intravitreous (IVT) triamcinolone acetonide to antivascular endothelial growth factor (VEGF) injections to IVT anti-VEGF injections alone for center-involving diabetic macular edema (DME) in treatment-naïve eyes. Methods. Retrospective study o...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2016/5282470 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566219205509120 |
|---|---|
| author | Robert B. Garoon Robert E. Coffee Lai Jiang Christina Y. Weng Petros E. Carvounis |
| author_facet | Robert B. Garoon Robert E. Coffee Lai Jiang Christina Y. Weng Petros E. Carvounis |
| author_sort | Robert B. Garoon |
| collection | DOAJ |
| description | Aims. To compare visual and anatomic outcomes of adjunct intravitreous (IVT) triamcinolone acetonide to antivascular endothelial growth factor (VEGF) injections to IVT anti-VEGF injections alone for center-involving diabetic macular edema (DME) in treatment-naïve eyes. Methods. Retrospective study of treatment-naïve eyes with center-involving DME. The primary outcome was the change in best corrected visual acuity (BCVA) in eyes receiving only IVT anti-VEGF (group 1) and eyes receiving IVT anti-VEGF and adjunct IVT-TA (group 2). Results. Included were 192 eyes. The mean change in BCVA was +3.5 letters in group 1 compared to −3.5 letters in group 2 (p=0.048). Final macular thickness improved by −94 μm in group 1 versus −68 μm in group 2 (p=0.26). In group 1, 5/150 eyes compared to 9/42 eyes in group 2 (3.3% versus 21%, p=0.0005) had a IOP >10 mmHg increase. Six of 126 phakic eyes in group 1 versus 12/33 phakic eyes in group 2 underwent cataract surgery (4.7% versus 36.3%, p=0.00009). Conclusions. IVT-TA results in no additional benefit in eyes treated with anti-VEGF agents for DME. |
| format | Article |
| id | doaj-art-86d84b97e39a4e78921d1c300eac024b |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-86d84b97e39a4e78921d1c300eac024b2025-02-03T01:04:48ZengWileyJournal of Ophthalmology2090-004X2090-00582016-01-01201610.1155/2016/52824705282470Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF AgentsRobert B. Garoon0Robert E. Coffee1Lai Jiang2Christina Y. Weng3Petros E. Carvounis4Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USACullen Eye Institute, Baylor College of Medicine, Houston, TX, USASchool of Medicine, Baylor College of Medicine, Houston, TX, USACullen Eye Institute, Baylor College of Medicine, Houston, TX, USACullen Eye Institute, Baylor College of Medicine, Houston, TX, USAAims. To compare visual and anatomic outcomes of adjunct intravitreous (IVT) triamcinolone acetonide to antivascular endothelial growth factor (VEGF) injections to IVT anti-VEGF injections alone for center-involving diabetic macular edema (DME) in treatment-naïve eyes. Methods. Retrospective study of treatment-naïve eyes with center-involving DME. The primary outcome was the change in best corrected visual acuity (BCVA) in eyes receiving only IVT anti-VEGF (group 1) and eyes receiving IVT anti-VEGF and adjunct IVT-TA (group 2). Results. Included were 192 eyes. The mean change in BCVA was +3.5 letters in group 1 compared to −3.5 letters in group 2 (p=0.048). Final macular thickness improved by −94 μm in group 1 versus −68 μm in group 2 (p=0.26). In group 1, 5/150 eyes compared to 9/42 eyes in group 2 (3.3% versus 21%, p=0.0005) had a IOP >10 mmHg increase. Six of 126 phakic eyes in group 1 versus 12/33 phakic eyes in group 2 underwent cataract surgery (4.7% versus 36.3%, p=0.00009). Conclusions. IVT-TA results in no additional benefit in eyes treated with anti-VEGF agents for DME.http://dx.doi.org/10.1155/2016/5282470 |
| spellingShingle | Robert B. Garoon Robert E. Coffee Lai Jiang Christina Y. Weng Petros E. Carvounis Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents Journal of Ophthalmology |
| title | Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents |
| title_full | Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents |
| title_fullStr | Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents |
| title_full_unstemmed | Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents |
| title_short | Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents |
| title_sort | adjunct intravitreous triamcinolone acetonide in the treatment of diabetic macular edema with anti vegf agents |
| url | http://dx.doi.org/10.1155/2016/5282470 |
| work_keys_str_mv | AT robertbgaroon adjunctintravitreoustriamcinoloneacetonideinthetreatmentofdiabeticmacularedemawithantivegfagents AT robertecoffee adjunctintravitreoustriamcinoloneacetonideinthetreatmentofdiabeticmacularedemawithantivegfagents AT laijiang adjunctintravitreoustriamcinoloneacetonideinthetreatmentofdiabeticmacularedemawithantivegfagents AT christinayweng adjunctintravitreoustriamcinoloneacetonideinthetreatmentofdiabeticmacularedemawithantivegfagents AT petrosecarvounis adjunctintravitreoustriamcinoloneacetonideinthetreatmentofdiabeticmacularedemawithantivegfagents |